Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
BACKGROUND
Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.


OBJECTIVE
To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.


RESULTS
After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor.


CONCLUSIONS
Imiquimod 5% cream may be another treatment modality for nodular BCC.
Huber
Amy
A
Department of Medicine, Division of Dermatology, University of Tennessee, Memphis, USA.
Huber
John D
JD
Skinner
Robert B
RB
Kuwahara
Raymond T
RT
Haque
Raashid
R
Amonette
Rex A
RA
D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D000077271:Imiquimod; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy*
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod